Bridgeway Capital Management’s Damora Therapeutics DMRA Stock Holding History

Bridgeway Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,924	Closed	-$57K	–	1298
2024 Q1	$57K	Sell	2,924 -2,000	-41%	-$35.6K	﹤0.01%	1259
2023 Q4	$88.6K	Sell	4,924 -2,000	-29%	-$30.8K	﹤0.01%	1257
2023 Q3	$125K	Hold	6,924	–	–	﹤0.01%	1185
2023 Q2	$436K	Hold	6,924	–	–	0.01%	939
2023 Q1	$344K	Hold	6,924	–	–	0.01%	975
2022 Q4	$199K	Hold	6,924	–	–	0.01%	1089
2022 Q3	$327K	Hold	6,924	–	–	0.01%	1011
2022 Q2	$299K	Sell	6,924 -400	-5%	-$18.3K	0.01%	996
2022 Q1	$403K	Hold	7,324	–	–	0.01%	996
2021 Q4	$555K	Sell	7,324 -4,000	-35%	-$314K	0.01%	952
2021 Q3	$1.02M	Buy	11,324 +3,000	+36%	+$321K	0.02%	820
2021 Q2	$1.05M	Buy	+8,324	New	+$1.13M	0.02%	839

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bridgeway Capital Management's DMRA Position: Q2 2024 in Review

Bridgeway Capital Management sold out of Damora Therapeutics (DMRA) in Q2 2024, closing a stake of 2,924 shares — an estimated $57K sold.

Bridgeway Capital Management first reported a position in DMRA in Q2 2021 and held it in 12 quarters. The position peaked at $1.05M in Q2 2021. 22 funds tracked by Wall St. Rank hold DMRA as of Q2 2024.

Bridgeway Capital Management reported no remaining Damora Therapeutics position as of Q2 2024 after selling out during the quarter.
Bridgeway Capital Management sold 2,924 Damora Therapeutics shares in Q2 2024, an estimated $57K.
Bridgeway Capital Management first reported a position in Damora Therapeutics in Q2 2021 and held it in 12 quarters.
Bridgeway Capital Management's Damora Therapeutics position peaked at $1.05M in Q2 2021.
22 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2024.

Based on Bridgeway Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.